Botanical & Pharmacological Identification
The Eight Factors
Actual or Relative Potential for Abuse
Mitragynine acts as a partial μ-opioid agonist; 7-hydroxymitragynine binds μ-opioid receptors with markedly higher affinity. Animal intravenous self-administration models show reinforcing behavior, though generally below oxycodone and morphine benchmarks. Human clinical euphoria reports are dose-dependent and attenuated relative to classical opioids.
Pharmacological Effect Evidence
Biphasic CNS profile: stimulant and (low dose) adrenergic activity shifting to opioid-like CNS depression at higher doses. Demonstrates analgesia, sedation, and pupillary constriction consistent with opioid pharmacodynamics.
Current Scientific Knowledge
Alkaloid chemistry is well characterized. Chemotype differentiation between traditional SE-Asian leaf and US-grown or concentrated extract is a critical unresolved variable. Metabolic conversion of mitragynine to the more potent 7-OH in vivo is established but inter-individual CYP2D6 variability is not fully quantified.
Pattern of Abuse
Documented historical use in Southeast Asia as a labor stimulant and opium substitute. U.S. poison-center call volume and exposure reports rose materially over the past decade, driven largely by non-leaf concentrated and adulterated products rather than traditional leaf preparations.
Scope & Duration of Abuse
Widespread availability through unregulated online channels. Use scope is broad but concentrated in self-managed pain and opioid-withdrawal populations rather than general recreational markets. Duration signal is sustained and growing.
Public Health Risk
Adverse events include hepatic injury, seizures, and respiratory depression — predominantly in polydrug combinations with benzodiazepines, alcohol, or opioids. Reported fatalities are overwhelmingly polysubstance. Public-health threat is material, especially for concentrated 7-OH-enriched products.
Psychic or Physiological Dependence
A withdrawal syndrome is documented — rhinorrhea, myalgia, insomnia, irritability — consistent with opioid-spectrum dependence but typically mild-to-moderate in severity. Dependency potential rises with extract concentration and frequency of use.
Immediate Precursor Status
Neither mitragynine nor 7-hydroxymitragynine is a direct scheduled-precursor under 21 CFR § 1308. Mitragynine is, however, the in-vivo precursor to the higher-affinity 7-OH; concentrated 7-OH products effectively constitute a pharmacologically amplified derivative.
Risk & Evidence Matrix
Scheduling Recommendation
The totality of evidence supports a differentiated posture. Raw, traditional-chemotype leaf exhibits moderate abuse liability with attenuated reinforcement relative to classical opioids and supports continued unscheduled status pending further controlled clinical data. Concentrated and 7-hydroxymitragynine-enriched products, however, carry elevated public-health risk via amplified μ-opioid activity and polydrug fatalities — supporting placement under controlled-substance oversight (Schedule III–IV tier warranting further evaluation).
Chemotype standardization (USP-grade HPLC profiling of the mitragynine / 7-OH ratio) and exclusion of aerial-part pipermethystine-type adulterants are prerequisites to any regulatory pathway.
Critical Gaps & Validation Metrics
- Distinction between noble / traditional chemotypes and concentrated 7-OH-enriched extracts is not yet standardized across the literature.
- Batches require UHPLC-PDA-CAD-HRMS profiling to establish a fixed mitragynine / 7-hydroxymitragynine ratio and prove absence of synthetic adulterants.
- Controlled human pharmacokinetic / abuse-liability studies (vs. oxycodone comparator) remain limited and are required to finalize the scheduling determination.
This brief is an educational regulatory-analysis framework mimicking the 8-Factor Analysis structure. It does not constitute official FDA/DEA scheduling determinations, legal advice, or clinical guidance.